Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in clinical vertebral fractures compared with placebo (low certainty).
1 finding from 1 review
RR 3.03 [0.32, 28.44]
Studies not reported
Low
Wrist fractures · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.9 [0.13, 6.04]
Studies not reported
Very low
Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.54, 2.18]
Studies not reported
Very low
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.56 [0.2, 1.61]
Studies not reported
Moderate
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Wrist fractures · postmenopausal women at lower risk of fractures1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 1.41 [0.81, 2.47]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Clinical vertebral fractures · postmenopausal women with a higher risk for fracturesa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐vertebral fractures · postmenopausal women with a higher risk for fracturesa
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in non‐vertebral fractures compared with placebo (low certainty).
1 finding from 1 review
RR 1.07 [0.72, 1.58]
Studies not reported
Low
Hip Fracture · postmenopausal women with a higher risk for fracturesa
It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes hip fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.93 [0.17, 5.19]
Studies not reported
Very low